Ring Finger Protein 1, a Novel Ubiquitin E3 Ligase Targeting Cancerous Inhibitor of Protein Phosphatase 2A to Suppress Smoking-Induced Lung Tumorigenesis

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that promotes cancer cell proliferation, invasion, and drug resistance. In this study, CIP2A expression was found to be higher in lung cancer tissues compared to adjacent normal tissues. Knocking down CIP2A in lung cancer cells reduced cell proliferation and migration. Ring finger protein 1 (RING1), a member of the RING family in the ubiquitin–proteasome system, was identified as a potential E3 ligase for CIP2A. The interaction between RING1 and CIP2A was confirmed, with RING1 regulating CIP2A ubiquitination. Knockdown of RING1 increased lung cancer cell proliferation and migration in vitro and in vivo, linked to the upregulation of CIP2A and its downstream molecules, c-MYC and Cyclin B1. Smoking's impact on RING1 expression was examined using cigarette smoke extract (CSE), which decreased RING1 mRNA and protein levels. This led to CIP2A and c-MYC upregulation. The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a constituent of CSE, downregulated RING1 expression through DNA methyltransferase 1 (DNMT1) activation, whereas inhibition of DNMT1 restored RING1 levels. These findings highlight the DNMT1–RING1–CIP2A axis in lung cancer progression due to smoking and suggest potential therapeutic and diagnostic targets.

Keywords

cancerous inhibitor of protein phosphatase 2A / DNA methyltransferase 1 / lung cancer / ring finger protein 1 / ubiquitin–proteasome system

References

[1] R. Jenkins, J. Walker, and U. B. Roy, “2022 Cancer Statistics: Focus on Lung Cancer,” Future Oncology 21 (2023): 3447–3457.

[2] K. D. Miller, L. Nogueira, A. B. Mariotto, et al., “Cancer Treatment and Survivorship Statistics, 2019,” CA 69, no. 5 (2019): 363–385.

[3] Z. R. Zheng, H. Y. Ku, K. C. Chen, et al., “Association of Smoking and ALK Tyrosine-Kinase Inhibitors on Overall Survival in Treatment-Naive ALK-Positive Advanced Lung Adenocarcinoma,” Frontiers in Oncology 13 (2023): 1063695.

[4] X. Fang, E. Huang, X. Xie, et al., “A Novel Senescence-Related lncRNA Signature That Predicts Prognosis and the Tumor Microenvironment in Patients With Lung Adenocarcinoma,” Frontiers in Genetics 13 (2022): 951311.

[5] K. Hosseini, H. Ahangari, F. Chapeland-Leclerc, G. Ruprich-Robert, V. Tarhriz, and A. Dilmaghani, “Role of Fungal Infections in Carcinogenesis and Cancer Development: A Literature Review,” Advanced Pharmaceutical Bulletin 12, no. 4 (2022): 747–756.

[6] C. Qi, S. W. Sun, and X. Z. Xiong, “From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis,” International Journal of Chronic Obstructive Pulmonary Disease 17 (2022): 2603–2621.

[7] Z. Wu, T. Yao, Z. Wang, et al., “Association Between Angiotensin-Converting Enzyme Inhibitors and the Risk of Lung Cancer: A Systematic Review and Meta-Analysis,” British Journal of Cancer 128, no. 2 (2023): 168–176.

[8] A. G. Wylie and A. A. Korchevskiy, “Dimensions of Elongate Mineral Particles and Cancer: A Review,” Environmental Research 230 (2022): 114688.

[9] P. De, J. Carlson, B. Leyland-Jones, and N. Dey, “Oncogenic Nexus of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): An Oncoprotein With Many Hands,” Oncotarget 5, no. 13 (2014): 4581–4602.

[10] M. R. Junttila, P. Puustinen, M. Niemela, et al., “CIP2A Inhibits PP2A in Human Malignancies,” Cell 130, no. 1 (2007): 51–62.

[11] B. Chen, H. Hu, and X. Chen, “From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer,” Frontiers in Genetics 14 (2023): 1110656.

[12] I. Cristobal, F. Rojo, J. Madoz-Gurpide, and J. Garcia-Foncillas, “Cross Talk Between Wnt/Beta-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications,” Molecular and Cellular Biology 36, no. 12 (2016): 1734–1739.

[13] P. De, J. H. Carlson, B. Leyland-Jones, and N. Dey, “Role of “Oncogenic Nexus” of CIP2A in Breast Oncogenesis: How Does It Work?,” American Journal of Cancer Research 5, no. 9 (2015): 2872–2891.

[14] H. Fujiki, E. Sueoka, T. Watanabe, and M. Suganuma, “The Concept of the Okadaic Acid Class of Tumor Promoters Is Revived in Endogenous Protein Inhibitors of Protein Phosphatase 2A, SET and CIP2A, in human Cancers,” Journal of Cancer Research and Clinical Oncology 144, no. 12 (2018): 2339–2349.

[15] C. S. Hong, W. Ho, C. Zhang, C. Yang, J. B. Elder, and Z. Zhuang, “LB100, a Small Molecule Inhibitor of PP2A With Potent Chemo- and Radio-Sensitizing Potential,” Cancer Biology & Therapy 16, no. 6 (2015): 821–833.

[16] A. Khanna, J. E. Pimanda, and J. Westermarck, “Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target,” Cancer Research 73, no. 22 (2013): 6548–6553.

[17] A. Laine and J. Westermarck, “Molecular Pathways: Harnessing E2F1 Regulation for Prosenescence Therapy in p53-Defective Cancer Cells,” Clinical Cancer Research 20, no. 14 (2014): 3644–3650.

[18] A. Khanna and J. E. Pimanda, “Clinical Significance of Cancerous Inhibitor of Protein Phosphatase 2A in Human Cancers,” International Journal of Cancer 138, no. 3 (2016): 525–532.

[19] M. R. Junttila and J. Westermarck, “Mechanisms of MYC Stabilization in Human Malignancies,” Cell Cycle 7, no. 5 (2008): 592–596.

[20] Y. C. Lin, K. C. Chen, C. C. Chen, A. L. Cheng, and K. F. Chen, “CIP2A-Mediated Akt Activation Plays a Role in Bortezomib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells,” Oral Oncology 48, no. 7 (2012): 585–593.

[21] C. Y. Liu, M. H. Hu, C. J. Hsu, et al., “Lapatinib Inhibits CIP2A/PP2A/p-Akt Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells,” Oncotarget 7, no. 8 (2016): 9135–9149.

[22] M. Luque, I. Cristobal, M. Sanz-Alvarez, et al., “CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer,” Journal of Clinical Medicine 11, no. 6 (2022): 1610.

[23] A. Laine, H. Sihto, C. Come, et al., “Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop Between CIP2A and E2F1,” Cancer Discovery 3, no. 2 (2013): 182–197.

[24] S. Liu, X. Bu, A. Kan, et al., “SP1-Induced lncRNA DUBR Promotes Stemness and Oxaliplatin Resistance of Hepatocellular Carcinoma via E2F1-CIP2A Feedback,” Cancer Letters 528 (2022): 16–30.

[25] X. Wang, P. Gao, M. Wang, et al., “Feedback Between E2F1 and CIP2A Regulated by Human Papillomavirus E7 in Cervical Cancer: Implications for Prognosis,” American Journal of Translational Research 9, no. 5 (2017): 2327–2339.

[26] D. Nandi, P. Tahiliani, A. Kumar, and D. Chandu, “The Ubiquitin-Proteasome System,” Journal of Biosciences 31, no. 1 (2006): 137–155.

[27] S. J. Thompson, L. T. Loftus, M. D. Ashley, and R. Meller, “Ubiquitin-Proteasome System as a Modulator of Cell Fate,” Current Opinion in Pharmacology 8, no. 1 (2008): 90–95.

[28] D. P. Satijn, M. J. Gunster, J. van der Vlag, et al., “RING1 is Associated With the Polycomb Group Protein Complex and Acts as a Transcriptional Repressor,” Molecular and Cellular Biology 17, no. 7 (1997): 4105–4113.

[29] J. Shen, P. Li, X. Shao, et al., “The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival,” Cancer Research 78, no. 2 (2018): 359–371.

[30] D. M. Heery, “A Fellowship of Ring1 Maintains AML Stem Cells,” Blood 131, no. 16 (2018): 1771–1773.

[31] S. B. Pierce, M. D. Stewart, S. Gulsuner, et al., “De Novo Mutation in RING1 With Epigenetic Effects on Neurodevelopment,” PNAS 115, no. 7 (2018): 1558–1563.

[32] S. S. Lin, R. Martin, S. Mongrand, et al., “RING1 E3 Ligase Localizes to Plasma Membrane Lipid Rafts to Trigger FB1-Induced Programmed Cell Death in Arabidopsis,” Plant Journal 56, no. 4 (2008): 550–561.

[33] Y. Zhou, C. Wan, Y. Liu, et al., “Polycomb Group Oncogene RING1 Is Over-Expressed in Non-Small Cell Lung Cancer,” Pathology Oncology Research 20, no. 3 (2014): 549–556.

[34] K. Zhu, J. Li, J. Li, et al., “Ring1 Promotes the Transformation of Hepatic Progenitor Cells Into Cancer Stem Cells Through the Wnt/Beta-Catenin Signaling Pathway,” Journal of Cellular Biochemistry 121, no. 8–9 (2020): 3941–3951.

[35] H. Qin, J. Wang, Y. Liang, Y. Taniguchi, K. Tanigaki, and H. Han, “RING1 Inhibits Transactivation of RBP-J by Notch Through Interaction With LIM Protein KyoT2,” Nucleic Acids Research 32, no. 4 (2004): 1492–1501.

[36] X. Rui, Y. Xu, X. Jiang, W. Ye, Y. Huang, and J. Jiang, “Long Non-Coding RNA C5orf66-AS1 Promotes Cell Proliferation in Cervical Cancer by Targeting miR-637/RING1 Axis,” Cell Death & Disease 9, no. 12 (2018): 1175.

[37] S. Gao, S. Y. Wang, X. D. Zhang, H. Wu, and D. Pang, “Low Expression of the Polycomb Protein RING1 Predicts Poor Prognosis in Human Breast Cancer,” Frontiers in Oncology 10 (2020): 618768.

[38] J. Xue, S. Yang, and S. Seng, “Mechanisms of Cancer Induction by Tobacco-Specific NNK and NNN,” Cancers 6, no. 2 (2014): 1138–1156.

[39] G. Z. Ge, T. R. Xu, and C. Chen, “Tobacco Carcinogen NNK-Induced Lung Cancer Animal Models and Associated Carcinogenic Mechanisms,” Acta Biochimica et Biophysica Sinica 47, no. 7 (2015): 477–487.

[40] N. Hirata, S. Yamada, Y. Sekino, and Y. Kanda, “Tobacco Nitrosamine NNK Increases ALDH-Positive Cells via ROS-Wnt Signaling Pathway in A549 Human Lung Cancer Cells,” Journal of Toxicological Sciences 42, no. 2 (2017): 193–204.

[41] R. Y. Huang, M. Y. Li, M. K. Hsin, et al., “4-Methylnitrosamino-1-3-Pyridyl-1-Butanone (NNK) Promotes Lung Cancer Cell Survival by Stimulating Thromboxane A2 and Its Receptor,” Oncogene 30, no. 1 (2011): 106–116.

[42] R. R. Hudlikar, D. Sargsyan, D. Cheng, et al., “Tobacco Carcinogen 4-[Methyl(Nitroso)Amino]-1-(3-Pyridinyl)-1-Butanone (NNK) Drives Metabolic Rewiring and Epigenetic Reprograming in A/J Mice Lung Cancer Model and Prevention With Diallyl Sulphide (DAS),” Carcinogenesis 43, no. 2 (2022): 140–149.

[43] C. Li, J. D. Schuetz, and A. P. Naren, “Tobacco Carcinogen NNK Transporter MRP2 Regulates CFTR Function in Lung Epithelia: Implications for Lung Cancer,” Cancer Letters 292, no. 2 (2010): 246–253.

[44] Y. Wang, L. Shi, J. Li, H. Wang, and H. Yang, “Involvement of Twist in NNK Exposure-Promoted Lung Cancer Cell Migration and Invasion,” Toxicology In Vitro 63 (2020): 104740.

[45] X. Chen, W. Zhang, R. Liu, et al., “NNK From Tobacco Smoking Enhances Pancreatic Cancer Cell Stemness and Chemoresistance by Creating a beta2AR-Akt Feedback Loop That Activates Autophagy,” Molecular Oncology 16, no. 15 (2022): 2881–2895.

[46] H. Pham, M. Chen, H. Takahashi, et al., “Apigenin Inhibits NNK-Induced Focal Adhesion Kinase Activation in Pancreatic Cancer Cells,” Pancreas 41, no. 8 (2012): 1306–1315.

[47] D. Zhang, J. Lei, J. Ma, et al., “beta2-Adrenogenic Signaling Regulates NNK-Induced Pancreatic Cancer Progression via Upregulation of HIF-1alpha,” Oncotarget 7, no. 14 (2016): 17760–17772.

[48] C. J. Chung, H. L. Lee, H. Y. Yang, et al., “Low Ratio of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol-Glucuronides (NNAL-Gluc)/Free NNAL Increases Urothelial Carcinoma Risk,” Science of the Total Environment 409, no. 9 (2011): 1638–1642.

[49] “Expression of Concern: Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer,” Cancer Prevention Research 12, no. 10 (2019): 733–734.

[50] S. R. Davis, X. Tao, E. J. Bernacki, and A. S. Alfriend, “Evaluation of a Bladder Cancer Cluster in a Population of Criminal Investigators With the Bureau of Alcohol, Tobacco, Firearms and Explosives-Part 1: The Cancer Incidence,” Journal of Environmental and Public Health 2012 (2012): 101850.

[51] D. Dowdy, “Tobacco Smoking and Bladder Cancer,” JAMA 306, no. 20 (2011): 2216–2217.

[52] F. Jin, J. Thaiparambil, S. R. Donepudi, et al., “Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer,” Cancer Prevention Research 10, no. 10 (2017): 588–597.

[53] W. Wang, H. Chin-Sheng, L. J. Kuo, et al., “NNK Enhances Cell Migration Through Alpha7-Nicotinic Acetylcholine Receptor Accompanied by Increased of Fibronectin Expression in Gastric Cancer,” Annals of Surgical Oncology 19, supplement, no. S3 (2012): S580–5588.

[54] S. G. Doukas, D. P. Vageli, G. Lazopoulos, D. A. Spandidos, C. T. Sasaki, and A. Tsatsakis, “The Effect of NNK, a Tobacco Smoke Carcinogen, on the miRNA and Mismatch DNA Repair Expression Profiles in Lung and Head and Neck Squamous Cancer Cells,” Cells 9, no. 4 (2020): 1031.

[55] S. Hati, Q. Hu, Z. Huo, J. Lu, and C. Xing, “In Vivo Structure-Activity Relationship of Dihydromethysticin in Reducing Nicotine-Derived Nitrosamine Ketone (NNK)-Induced Lung DNA Damage Against Lung Carcinogenesis in A/J Mice,” ChemMedChem 17, no. 7 (2022): e202100727.

[56] S. Arimoto-Kobayashi, H. Sakata, K. Mitsu, and H. Tanoue, “A Possible Photosensitizer: Tobacco-Specific Nitrosamine, 4-(N-Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK), Induced Mutations, DNA Strand Breaks and Oxidative and Methylative Damage With UVA,” Mutation Research 632, no. 1–2 (2007): 111–120.

[57] M. A. Sipowicz, S. Amin, D. Desai, K. S. Kasprzak, and L. M. Anderson, “Oxidative DNA Damage in Tissues of Pregnant Female Mice and Fetuses Caused by the Tobacco-Specific Nitrosamine, 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK),” Cancer Letters 117, no. 1 (1997): 87–91.

[58] C. Croccia, A. J. Lopes, L. F. Pinto, et al., “Royal Sun Medicinal Mushroom Agaricus Brasiliensis (Higher Basidiomycetes) and the Attenuation of Pulmonary Inflammation Induced by 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK),” International Journal of Medicinal Mushrooms 15, no. 4 (2013): 345–355.

[59] Q. Hua, Y. Liu, M. Li, X. Li, W. Chen, and Q. Diao, “Upregulation of Circ_0035266 Contributes to the Malignant Progression of Inflammation-Associated Malignant Transformed Cells Induced by Tobacco-Specific Carcinogen NNK,” Toxicological Sciences 189, no. 2 (2022): 203–215.

[60] P. Keohavong, B. Kahkonen, E. Kinchington, et al., “K-ras Mutations in Lung Tumors From NNK-Treated Mice With Lipopolysaccharide-Elicited Lung Inflammation,” Anticancer Research 31, no. 9 (2011): 2877–2882.

[61] X. Deng, “Bcl2 Family Functions as Signaling Target in Nicotine-/NNK-Induced Survival of Human Lung Cancer Cells,” Scientifica 2014 (2014): 215426.

[62] J. Shen, L. Xu, T. K. Owonikoko, et al., “NNK Promotes Migration and Invasion of Lung Cancer Cells Through Activation of c-Src/PKCiota/FAK Loop,” Cancer Letters 318, no. 1 (2012): 106–113.

[63] S. Balbo, P. Upadhyaya, P. W. Villalta, X. Qian, and F. Kassie, “DNA Adducts in Aldehyde Dehydrogenase-Positive Lung Stem Cells of A/J Mice Treated With the Tobacco Specific Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK),” Chemical Research in Toxicology 26, no. 4 (2013): 511–513.

[64] R. Ziegel, A. Shallop, R. Jones, and N. Tretyakova, “K-ras Gene Sequence Effects on the Formation of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK)-DNA Adducts,” Chemical Research in Toxicology 16, no. 4 (2003): 541–550.

[65] R. K. Lin, Y. S. Hsieh, P. Lin, et al., “The Tobacco-Specific Carcinogen NNK Induces DNA Methyltransferase 1 Accumulation and Tumor Suppressor Gene Hypermethylation in Mice and Lung Cancer Patients,” Journal of Clinical Investigation 120, no. 2 (2010): 521–532.

[66] J. Wang, Y. Xu, J. Li, X. Sun, L. P. Wang, and W. Y. Ji, “The Tobacco-Specific Carcinogen NNK Induces DNA Methyltransferase 1 Accumulation in Laryngeal Carcinoma,” Oral Oncology 48, no. 6 (2012): 541–546.

[67] J. O. Jin, G. D. Lee, S. H. Nam, et al., “Sequential Ubiquitination of p53 by TRIM28, RLIM, and MDM2 in Lung Tumorigenesis,” Cell Death and Differentiation 28, no. 6 (2021): 1790–1803.

[68] W. J. Su, J. S. Fang, F. Cheng, C. Liu, F. Zhou, and J. Zhang, “RNF2/Ring1b Negatively Regulates p53 Expression in Selective Cancer Cell Types to Promote Tumor Development,” PNAS 110, no. 5 (2013): 1720–1725.

[69] M. Carbone, J. W. Harbour, J. Brugarolas, et al., “Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer,” Cancer Discovery 10, no. 8 (2020): 1103–1120.

[70] L. Tao, X. Liu, X. Jiang, et al., “USP10 as a Potential Therapeutic Target in Human Cancers,” Genes 13, no. 5 (2022): 831.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.